CO4950513A1 - Compuestos de pirazina - Google Patents
Compuestos de pirazinaInfo
- Publication number
- CO4950513A1 CO4950513A1 CO98010500A CO98010500A CO4950513A1 CO 4950513 A1 CO4950513 A1 CO 4950513A1 CO 98010500 A CO98010500 A CO 98010500A CO 98010500 A CO98010500 A CO 98010500A CO 4950513 A1 CO4950513 A1 CO 4950513A1
- Authority
- CO
- Colombia
- Prior art keywords
- 4alkyl
- substituted
- hydrogen
- group
- halogen atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Detergent Compositions (AREA)
Abstract
Un compuesto de fórmula (I)caracterizado porque R1 se selecciona del grupo que consiste de fenilo sustituido por uno o más átomos de halógeno, naftilo y naftilo sustituido por uno o más átomos de halógeno; R2 se selecciona del grupo que consiste de -NH2 y -NHC(=O)Ra ; R3 se selecciona del grupo que consiste de -NRb Rc , -NHC(=O)Ra e hidrógeno; R4 se selecciona del grupo que consiste de hidrógeno, -alquilo de C1-4 , -alquilo de C1-4 sustituido por uno o más átomos de halógeno, -CN, -CH2 OH, -CH2 ORd y -CH2 S(O)x Rd ; en la que Ra representa alquilo de C1-4 o cicloalquilo de C3-7 , y Rb y Rc , los cuales pueden ser los mismos o diferentes, se seleccionan de hidrógeno y alquilo de C1-4 , o junto con el átomo de nitrógeno al cual están unidos, forma un heterociclo de 6 miembros que contiene nitrógeno, el cual heterociclo puede ser además sustituido con uno o más de alquilo de C1-4 ; Rd se selecciona de alquilo C1-4 o alquilo de C1-4 sustituido por uno o más átomos de halógeno; x es un número entero de cero, uno o dos; y derivados farmacéuticamente aceptables de los mismos; con la condición de que R1 no represente; cuando R2 sea -NH2 , y ambos de R3 y R4 sean hidrógeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704275.8A GB9704275D0 (en) | 1997-03-01 | 1997-03-01 | Pharmacologically active compound |
| GBGB9708183.0A GB9708183D0 (en) | 1997-04-23 | 1997-04-23 | Pharmacologically active compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4950513A1 true CO4950513A1 (es) | 2000-09-01 |
Family
ID=26311097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98010500A CO4950513A1 (es) | 1997-03-01 | 1998-02-26 | Compuestos de pirazina |
Country Status (46)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420354B1 (en) | 1998-06-08 | 2002-07-16 | Advanced Medicine, Inc. | Sodium channel drugs and uses |
| GB9818881D0 (en) | 1998-08-28 | 1998-10-21 | Glaxo Group Ltd | Compounds |
| GB9907965D0 (en) * | 1999-04-09 | 1999-06-02 | Glaxo Group Ltd | Medical use |
| US6479498B1 (en) | 1999-06-04 | 2002-11-12 | Theravance, Inc. | Sodium channel drugs and uses |
| EP1500653A1 (en) * | 2000-02-16 | 2005-01-26 | Neurogen Corporation | Substituted arylpyrazines |
| KR20080021603A (ko) * | 2000-02-16 | 2008-03-07 | 뉴로젠 코포레이션 | 치환된 아릴피라진 |
| GB0010971D0 (en) * | 2000-05-05 | 2000-06-28 | Glaxo Group Ltd | Process |
| GB0016040D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| MXPA04004714A (es) * | 2001-11-21 | 2004-08-19 | Upjohn Co | Derivados de aril 1,4-pirazina sustituidos. |
| EP1458386B1 (en) * | 2001-12-27 | 2007-04-18 | Ortho-McNeil Pharmaceutical, Inc. | Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| WO2003091225A1 (en) * | 2002-04-26 | 2003-11-06 | Pharmacia & Upjohn Company | Substituted pyrazine derivatives |
| JP2006509729A (ja) | 2002-08-20 | 2006-03-23 | ニューロジェン・コーポレーション | Ｃｒｆ受容体モジュレータとしての５−置換−２−アリールピラジン類 |
| SE0203753D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| SE0203754D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| WO2004066987A2 (en) * | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Use of sodium channel modulators for treating gastrointestinal tract disorders |
| TW200510373A (en) * | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
| ES2567853T3 (es) | 2005-01-25 | 2016-04-26 | Synta Pharmaceuticals Corporation | Compuestos contra la inflamación y utilizaciones relacionadas con el sistema inmunitario |
| JP2008530131A (ja) * | 2005-02-15 | 2008-08-07 | ジャズ、ファーマシューティカルズ、インコーポレイテッド | 置換ピラジン化合物の徐放のための投薬形態および方法 |
| NL2000284C2 (nl) * | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| EP1984339A1 (en) * | 2006-01-23 | 2008-10-29 | Pfizer Limited | Pyridine derivatives as sodium channel modulators |
| WO2008135830A1 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Limited | N- [6-amino-s- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain |
| GB0800741D0 (en) | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| FR3001151B1 (fr) | 2013-01-21 | 2016-04-08 | Pf Medicament | Association d'un bloqueur de courant sodique lent et d'un inhibiteur du courant if sinusal et les compositions pharmarceutiques la contenant |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| PL3468972T3 (pl) | 2016-06-14 | 2020-11-16 | Novartis Ag | Związki i kompozycje do hamowania aktywności shp2 |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN108101857B (zh) * | 2016-11-24 | 2021-09-03 | 韶远科技（上海)有限公司 | 制取2-氨基-3-溴-6-氯吡嗪的可放大工艺 |
| CN107011273A (zh) * | 2017-05-04 | 2017-08-04 | 无锡捷化医药科技有限公司 | 一种合成6‑碘‑3‑(2,3‑二氯苯基)吡嗪‑2‑胺的方法 |
| BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| CN115611700B (zh) * | 2022-10-11 | 2024-06-14 | 辽宁东大光明化工科技有限责任公司 | 一种1-溴-2,5-二氯-3-氟苯的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4402958A (en) * | 1981-11-19 | 1983-09-06 | American Cyanamid Company | Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates |
| EP0288431B1 (de) | 1987-04-07 | 1992-08-19 | Ciba-Geigy Ag | 3H-1,2,3-Triazolo[4,5-d]pyrimidine |
| JPH08238778A (ja) * | 1995-03-07 | 1996-09-17 | Brother Ind Ltd | インク噴射装置の電極形成方法 |
-
1998
- 1998-02-23 MA MA24973A patent/MA26473A1/fr unknown
- 1998-02-24 PE PE1998000134A patent/PE58299A1/es not_active Application Discontinuation
- 1998-02-26 DE DE69818643T patent/DE69818643T2/de not_active Expired - Lifetime
- 1998-02-26 GE GEAP19984976A patent/GEP20012555B/en unknown
- 1998-02-26 IL IL13129398A patent/IL131293A/xx not_active IP Right Cessation
- 1998-02-26 MY MYPI98000852A patent/MY118612A/en unknown
- 1998-02-26 PT PT98913592T patent/PT966448E/pt unknown
- 1998-02-26 CN CN98804593A patent/CN1105111C/zh not_active Expired - Fee Related
- 1998-02-26 GT GT199800046A patent/GT199800046A/es unknown
- 1998-02-26 SK SK1173-99A patent/SK117399A3/sk unknown
- 1998-02-26 CO CO98010500A patent/CO4950513A1/es unknown
- 1998-02-26 CZ CZ19993111A patent/CZ295618B6/cs not_active IP Right Cessation
- 1998-02-26 ID IDW990951A patent/ID22850A/id unknown
- 1998-02-26 TR TR1999/02082T patent/TR199902082T2/xx unknown
- 1998-02-26 DK DK98913592T patent/DK0966448T3/da active
- 1998-02-26 AU AU68237/98A patent/AU732915B2/en not_active Ceased
- 1998-02-26 YU YU40799A patent/YU40799A/sh unknown
- 1998-02-26 JO JO19982035A patent/JO2035B1/en active
- 1998-02-26 US US09/380,062 patent/US6255307B1/en not_active Expired - Fee Related
- 1998-02-26 AP AP9901632A patent/AP9901632A0/xx unknown
- 1998-02-26 PL PL335441A patent/PL192864B1/pl unknown
- 1998-02-26 KR KR1019997007937A patent/KR100544263B1/ko not_active IP Right Cessation
- 1998-02-26 EE EEP199900376A patent/EE9900376A/xx unknown
- 1998-02-26 NZ NZ337121A patent/NZ337121A/xx not_active IP Right Cessation
- 1998-02-26 AT AT98913592T patent/ATE251143T1/de active
- 1998-02-26 BR BRPI9807814-3A patent/BR9807814B1/pt not_active IP Right Cessation
- 1998-02-26 EA EA199900687A patent/EA002102B1/ru not_active IP Right Cessation
- 1998-02-26 ES ES98913592T patent/ES2205469T3/es not_active Expired - Lifetime
- 1998-02-26 SI SI9830578T patent/SI0966448T1/xx unknown
- 1998-02-26 WO PCT/EP1998/001077 patent/WO1998038174A1/en active IP Right Grant
- 1998-02-26 EP EP98913592A patent/EP0966448B1/en not_active Expired - Lifetime
- 1998-02-26 JP JP53731098A patent/JP3369189B2/ja not_active Expired - Fee Related
- 1998-02-26 HU HU0001802A patent/HU225852B1/hu not_active IP Right Cessation
- 1998-02-26 CA CA002282585A patent/CA2282585C/en not_active Expired - Fee Related
- 1998-02-27 SV SV1998000029A patent/SV1998000029A/es not_active Application Discontinuation
- 1998-02-27 UY UY24911A patent/UY24911A1/es unknown
- 1998-02-27 HN HN1998000036A patent/HN1998000036A/es unknown
- 1998-02-27 AR ARP980100906A patent/AR011174A1/es active IP Right Grant
- 1998-02-27 PA PA19988448201A patent/PA8448201A1/es unknown
- 1998-02-27 HR HR9708183.0A patent/HRP980107A2/hr not_active Application Discontinuation
- 1998-03-03 TW TW087103079A patent/TW513416B/zh not_active IP Right Cessation
-
1999
- 1999-02-11 HN HN1999000019A patent/HN1999000019A/es unknown
- 1999-08-24 IS IS5163A patent/IS5163A/is unknown
- 1999-08-27 OA OA9900196A patent/OA11151A/en unknown
- 1999-08-31 NO NO19994213A patent/NO313383B1/no not_active IP Right Cessation
- 1999-09-09 BG BG103723A patent/BG103723A/bg unknown
-
2000
- 2000-04-10 HK HK00102173A patent/HK1023116A1/xx not_active IP Right Cessation
-
2001
- 2001-05-16 US US09/855,703 patent/US6599905B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4950513A1 (es) | Compuestos de pirazina | |
| NO884467L (no) | Analogifremgangsmaate for fremstilling av aminomethyloxooxazolidinyl-cykloalkylbenzenderivater. | |
| DK20290A (da) | Formuleringer med forsinket afgivelse | |
| NO883506L (no) | Fremgangsmaate for fremstilling av foretrede polyoksyalkylenderivater. | |
| TR200100432T2 (tr) | Hepatit C inhibitörü tri-peptidler | |
| RS49688B (sr) | Novi derivat 3-aril-2- hidroksipropionske kiseline (i) | |
| FI905535A0 (fi) | Foerfarande foer reproduktion av barrtraed genom somatisk embryogenes. | |
| FI860473A (fi) | Nya -(2-okso-2,4,5,6,7,7a -hexahydro-tieno(3,2-c)-5-pyridyl)fenylaettiksyraderivat, foerfarande foer deras framstaellning och deras terapeutiska anvaendning. | |
| NO912051L (no) | Fremgangsmaate for fremstilling av azolderivater. | |
| DE69027235D1 (de) | Xanthinderivate | |
| ATE179173T1 (de) | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy 1,3-propandiol-derivate | |
| SG44477A1 (en) | Fused polycyclic compounds compositions methods of manufacture and their use as paf antaginists anthihistamines and/or antiinflammatory agents | |
| NO912411D0 (no) | Fremgangsmaate for fremstilling av bicykliske heterocykliske forbindelser. | |
| DK24984D0 (da) | 6-(acylaminoaryl)-3(2h)-pyridazinonderivater og deres anvendelse som laegemidler | |
| DE68918802D1 (de) | Stickstoff enthaltende heterozyklische Derivate. | |
| NO905100D0 (no) | Fremgangsmaate for fremstilling av hardt sukkertoey med brusevirkning. | |
| ES2119874T3 (es) | Nuevos derivados de elipticina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| NO911541D0 (no) | Boreslam av skleroglukan. | |
| ATE57184T1 (de) | Gamma-carboline. | |
| FI882121A0 (fi) | Nya 4-bensyl-1-(2h) -ftalazinonderivat innehaollande en aminosyrarest. | |
| ATE106438T1 (de) | Benzotriazolderivate enthaltende schmiermittelzusammensetzungen. | |
| DE69004079D1 (de) | Antioxidationszusammensetzungen. | |
| NO905003D0 (no) | Fremgangsmaate for fremstilling av proteaseinhibitorer frapotetsaft. | |
| FI882020A (fi) | Nya 2-aminoalkyl-4-benzyl-1-(2h)-ftalazinonderivat. | |
| FI884618A0 (fi) | Anordning foer taendning och stabilisering av en svetsbaoge. |